Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION
Drug Injury Watch
by Tom Lamb
1w ago
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or "Eye Stroke", Can Cause Vision Loss   (Posted by Tom Lamb at Drug Injury Watch)   Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent finding that the active ingredient of these three drugs semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION). As background, NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, aft ..read more
Visit website
Syfovre Safety-Benefit Assessment by Europe's Drug Regulator Differs From FDA
Drug Injury Watch
by Tom Lamb
2w ago
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events"   (Posted by Tom Lamb at Drug Injury Watch)   There seems to be some disagreement about the Syfovre safety-benefit assessment when it comes to the US FDA and its European counterpart, the European Medicines Agency (EMA). In late June 2024, Europe’s drug regulator, the Committee for Medicinal Products for Human Use (CHMP), did not approve Syfovre for a second time, with Apellis Pharmaceuticals asserting it will continue its efforts to market Syfovre in Europe. From this Fi ..read more
Visit website
Wegovy, Rybelsus, and Ozempic Blood Clots Cases Are Not Part of Federal Court MDL at This Time
Drug Injury Watch
by Tom Lamb
2M ago
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis   (Posted by Tom Lamb at Drug Injury Watch)   Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. Semaglutide is associated with a significantly increased risk of blood clots. Drug injury lawsuits filed for people diagnosed with gastroparesis, gastric stasis, stomach paralysis, and other semaglutide-related stomach conditions are in this federal court MDL: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY ..read more
Visit website
Syfovre Retinal Vaso-occlusive Vasculitis Case Report Involving 78-year Old Woman With Vision Loss
Drug Injury Watch
by Tom Lamb
2M ago
She Went to the Local ER With Loss of Vision 11 Days After Receiving an Intravitreal Syfovre (Pegcetacoplan) Injection   (Posted by Tom Lamb at Drug Injury Watch)   In the March 2024 edition of the American Journal of Ophthalmology Case Reports medical journal, there is a Syfovre retinal vaso-occlusive vasculitis case report involving a 78-year old woman with vision loss that happened back in the first part of 2023. This article, "Retinal vasculitis following intravitreal pegcetacoplan administration", was initially submitted to that medical journal in July 2023 a ..read more
Visit website
Syfovre Eye Injury Cases: More Questions Than Answers One Year After First Reports
Drug Injury Watch
by Tom Lamb
3M ago
Retinal Vasculitis After Syfovre Injections: Etiology is Still Unknown and Incidence Rate Remains Unclear   (Posted by Tom Lamb at Drug Injury Watch)   Syfovre (pegcetacoplan) was approved by the FDA in February 2023 as an eye injection to treat geographic atrophy (GA), a relatively rare condition secondary to age-related macular degeneration. Beginning in April 2023, there have been reports of Syfovre eye injury cases, including (1) retinal vasculitis resulting in significant vision loss, and (2) intraocular inflammation without retinal vascular involvement. Syfovre e ..read more
Visit website
Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient's First Syfovre Injection
Drug Injury Watch
by Tom Lamb
4M ago
Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis   (Posted by Tom Lamb at Drug Injury Watch)   In late January 2024, a leading medical journal for ophthalmologists and retina specialists, the Journal of VitreoRetinal Diseases, published this Syfovre case report, "Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan", written by three authors affiliated with the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, in Miami, Florida. Here is the A ..read more
Visit website
"New" Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis
Drug Injury Watch
by Tom Lamb
5M ago
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes   (Posted by Tom Lamb at Drug Injury Watch)   Semaglutide-containing drugs that are being used for weight loss purposes include Ozempic, Rybelsus, and Wegovy. Somewhat hidden in a relatively recent medical journal article is the mention of a blood clots side effect of semaglutide weight-loss drugs like Ozempic, deep vein thrombosis (DVT). Remarkably, medical researchers found that semaglutide increased the risk of deep vein thrombosis by 266% when doi ..read more
Visit website
Gastroparesis Case Reports Involving the Use of GLP-1 Receptor Agonists Semaglutide and Dulaglutide
Drug Injury Watch
by Tom Lamb
5M ago
Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity   (Posted by Tom Lamb at Drug Injury Watch)   In this article, we present some gastroparesis case reports involving the use of GLP-1 receptor agonists semaglutide (e.g., Ozempic, Wegovy, Rybelsus) or dulaglutide (e.g., Trulicity) that have been published recently by medical journals. These gastroparesis case reports discuss specific patient profiles, related symptoms, and the diagnosis process for gastroparesis, a side effect of Ozempic, Wegov ..read more
Visit website
Prolia Increased Risk of Hypocalcemia in Patients With Chronic Kidney Disease (CKD) 40 Times More Than Pills
Drug Injury Watch
by Tom Lamb
6M ago
Prolia "Black Box" Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events to Death   (Posted by Tom Lamb at Drug Injury Watch)   A January 2024 JAMA Original Investigation article, "Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients", in summary, presents evidence of a Prolia increased risk of hypocalcemia in patients with chronic kidney disease (CKD) that can be 40 times more than bisphosphonate pills. From the "Key Points" beginning of this online JAMA article about Prolia and severe hypocalcemia ..read more
Visit website
Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections
Drug Injury Watch
by Tom Lamb
7M ago
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss   (Posted by Tom Lamb at Drug Injury Watch)   We have been writing about Syfovre drug safety developments having to do with retinal vasculitis cases and other eye-related side effects since July 2023. This latest article is about the November 2023 Syfovre label change that adds new warnings about retinal vasculitis and/or retinal vascular occlusion associated with Syfovre injections. For background, here is a general Syfovre timeline bringing us up to the present t ..read more
Visit website

Follow Drug Injury Watch on FeedSpot

Continue with Google
Continue with Apple
OR